SCHEMBL4666098

SCHEMBL4666098

Cc1ccc(S(=O)(=O)N(OC=O)c2ccc(Nc3cc(-c4ccc5c(ccn5CCCN5CCCC5)c4)ncn3)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 9/20 0.35
HTR6 P50406 1/20 0.35
BACE1 P56817 1/20 0.34
PAX8 Q06710 1/20 0.33
SRC P12931 1/20 0.32
HRH3 Q9Y5N1 2/20 0.32
ABL1 P00519 1/20 0.32
BCR P11274 1/20 0.32
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
GLA P06280 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALOX15 P16050 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667474 0.96 BACE1 (0.35) BPTFHTR6BACE1PAX8SRC
SCHEMBL4666150 0.95 BPTF (0.35) BPTFHTR6BACE1SRCABL1
SCHEMBL4664370 0.94 ABL1 (0.38) BPTFHTR6HRH3ABL1BCR
SCHEMBL4665744 0.93 MEN1 (0.38) BPTFHTR6ABL1BCRMEN1
SCHEMBL4664340 0.91 BACE1 (0.35) BPTFBACE1ABL1BCRMEN1
SCHEMBL4665810 0.90 ABL1 (0.39) HTR6ABL1BCRTP53
SCHEMBL4666209 0.90 ABL1 (0.38) BPTFABL1BCRTP53CYP1A2
SCHEMBL4666211 0.89 BPTF (0.40) BPTFHTR6BACE1ABL1BCR
SCHEMBL4667365 0.87 HTR6 (0.35) BPTFHTR6ABL1BCRMEN1
SCHEMBL4666161 0.87 ABL1 (0.36) BPTFHTR6ABL1BCRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 BPTF 2862/4885HTR6 826/4885BACE1 4299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.